Fortrea Names Anshul Thakral Chief Executive Officer
DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board.
Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders.
'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.'
'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.'
About Anshul Thakral
Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).
Cautionary Statement Regarding Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.
Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
America's economy faces a potential war shock: Surging oil prices
The American economy faces the unwelcome prospect of reignited inflation after the United States launched strikes on three nuclear facilities in Iran. High oil and gas prices are a near certainty, experts say. The big question now: How long will the fossil fuels price spike last? Oil prices are expected to rise by about $5 per barrel when markets open on Sunday, according to experts. 'We are looking at $80 oil on the open,' said Andy Lipow of Lipow Oil Associates. U.S. oil hasn't closed above $80 a barrel since January and has largely hovered between $60 and $75 a barrel since August 2024. Relatively tame oil prices have lowered gas prices to below $3 a gallon in many parts of the country, a major source of price relief for inflation-weary consumers. It's unclear if any major spike in oil prices will be sustained for a long period. Oil prices have risen about 10% since Israel's surprise attack on June 13 and then fell on Friday after U.S. President Donald Trump announced a two-week deadline on whether to strike Iran. 'One shouldn't necessarily assume that just because the price of oil goes up, it's going to stay there. It doesn't,' said Joe Brusuelas, chief economist for the accounting firm RSM. The direction oil prices take is likely to depend on whether Iran's parliament decides to block the Strait of Hormuz, a key trade route that accounts for about 20% of the world's crude oil. On Sunday, Iran's Foreign Minister Abbas Araghchi said his country has 'a variety of options' when deciding how to respond to the U.S. attacks and a prominent adviser to Iran's supreme leader has already called for the closure of the Strait of Hormuz. Bob McNally, president of consulting firm Rapidan Energy Group and former energy adviser to President George W. Bush, said that should Iran cut off the world's oil supply by closing the strait it would risk more military force from the United States and its allies. Iran could also attack infrastructure in the Persian Gulf that treats and exports oil and gas. 'It's possible they will decide the only thing that can dissuade President Trump is the fear of an oil price spike,' he said. 'They have to actually create that fear.' Appearing Sunday on Fox News, Secretary of State Marco Rubio called on China to prevent Iran from closing the Strait of Hormuz, adding that closing it would do more damage to other economies than the U.S. economy. China buys a third of all oil that comes from the Persian Gulf, while the United States buys less than 3%. 'I encourage the Chinese government in Beijing to call them about that, because they heavily depend on the Straits of Hormuz for their oil,' Rubio said. Rubio added that closing the strait would hurt other countries' economies more than the U.S. economy. Meanwhile, American consumers may soon feel a price shock at the pump. 'It takes five days or so for stations to pass along the prices they see in one day. If oil markets do surge today and then tomorrow, it could start showing up at the pump in a matter of hours,' said Patrick De Haan, vice president of petroleum analysis at GasBuddy, a fuel tracking platform. According to Lipow, should the Strait of Hormuz be affected, the price of oil could rise to $100 a barrel, which would raise gas and diesel prices by about 75 cents per gallon from recent levels. Meanwhile, U.S. trade policies combined with the war with Iran 'strongly suggest inflation will be moving faster and higher over the next 90 days,' according to Brusuelas. Many mainstream economists argue that the low inflation of the spring represents a calm before the summer storm, when they expect prices to rise because of Trump's tariffs.
Globe and Mail
an hour ago
- Globe and Mail
Will Quantum Computing Stocks Soar in the Second Half?
Quantum computing stocks skyrocketed in 2024, with names such as Quantum Computing and Rigetti Computing surging by more than 1,000%. Investors were eager to get in on what could become the next game-changing technology, and revenue growth as well as scientific progress from some of these quantum specialists boosted optimism. Even after those gains, it's very possible that quantum stocks will climb in the second half of this year, and here's why. Why investors buy quantum computing stocks So, first, a quick note about why investors see so much potential in quantum computing. This is because this type of computing, based on quantum mechanics, makes it possible to solve problems that today's classic computers can't handle. Quantum computing can do this by using qubits -- instead of the bits used by today's computers -- to store data. And while bits store and process data as zeros or 1s, qubits can represent a zero, a one, or both at the same time. This allows for tremendous scaling, and as a result, a problem that would take a classic computer 1,000 years to solve may take a quantum machine about five minutes. Right now, quantum companies offer hardware and services to customers, but we're still in the early stages of development. Experts have said that truly useful quantum computers are several years away. The good news is that this means these companies have plenty of room to run when it comes to revenue growth and share price performance. It's clear that if quantum companies reach their development goals, these computers could revolutionize many industries. Quantum stocks in 2024 and 2025 All of this helped quantum computing pure-play companies climb last year. The bull market and optimism about the economy ahead offered the perfect environment for growth stocks to excel. But in recent months, concerns about President Donald Trump's import tariff plan weighed on these players. The idea was that tariffs could lead to higher prices at home, prompting customers of quantum companies to rein in their spending. But over the past few weeks, progress in trade talks and even initial deals with the U.K. and China have made investors more optimistic about the future. And corporate earnings haven't suggested any slowdown in spending on technology -- in fact, companies continue to reiterate their commitments to such projects. This backdrop supports the idea of more gains for quantum companies in the second half, especially for certain players such as Rigetti and IonQ, which haven't yet fully recovered -- they're down 25% and 5%, respectively, year to date. And if they show some growth in revenue in the coming quarters, this could act as a positive catalyst for share performance, too. Can D-Wave keep soaring? But this doesn't mean that stocks that have continued to advance, such as D-Wave Quantum (NYSE: QBTS), which is heading for an increase of more than 80%, won't keep on rising. For example, D-Wave just recently released its Advantage2 quantum computer, which is accessible both on the cloud and on-premises. More than 20 million customer problems have been run through the prototype, and the company says the computer is now ready for use in areas such as materials simulation and artificial intelligence (AI). Uptake of this new platform and further revenue gains -- D-Wave's revenue last quarter soared 500% to a record $15 million -- could offer this highflier an additional boost. Of course, it's important to keep in mind that these pure-play quantum companies aren't yet profitable and are involved in a relatively new, cutting-edge technology, and that involves some risk. Any economic headwinds could hurt investors' appetite for these sorts of players. These companies depend on a strong economy, as this increases the likelihood that potential customers will spend on their products and services. And investors generally feel more comfortable getting in on growth stocks when the economy is thriving. So, the economic situation in the second half could determine the near-term direction of these players. But right now, there's reason to be optimistic that the U.S. trade talks, along with some better-than-expected economic data, signal better days ahead -- and that the worst-case scenario of a recession and tough times for corporate earnings will be averted. With this in mind, quantum computing stocks could be set to soar in the second half as investors look to get in on the next big technology that could deliver explosive returns. Should you invest $1,000 in D-Wave Quantum right now? Before you buy stock in D-Wave Quantum, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and D-Wave Quantum wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor 's total average return is994% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
2 hours ago
- Globe and Mail
3 Dividend Aristocrats Ready for an (Upward) Technical Breakout
Technical analysis has always been a hit or miss for many investors. The guidelines and metrics can be as clear as day, but one must remember that the readings have to be taken with a grain of salt. Not only that, there's always the possibility of human error during analysis. Misinterpreting data and patterns or relying too heavily on specific indicators when a broader perspective would have been more ideal could result in an opposite desired outcome. Mix that with the various emotions that come from seeing the market go up and down on uncertain trade policies, and you have a recipe for disaster. Thankfully, Barchart has an objective way of compiling trade analysis and multiple data points into a simple yet elegant presentation called Trend Seeker ®. So today, let's use Trend Seeker ® in conjunction with one of my favorite income stock subsets - the Dividend Aristocrats - to evaluate which stocks have the strongest technical setups to act as a springboard for your long-term trading. How I Came Up With The Following Stocks Using Barchart's Stock Screener, I selected the following filters to get my list: Trend Seeker® Direction: Set at Strongest. Limits the results to stocks with a very strong bullish trend based on Trend Seeker®, which uses Barchart's computerized trend analysis system based on wave theory, market momentum, and volatility to identify potential buy and sell areas. Trend Seeker® Signal: Buy ratings based on Trend Seeker®'s analysis. Number of Analysts: 16 analysts. Indicator of a very high buy confidence in a stock. Current Analyst rating: Moderate to Strong Buy. Watchlist: Dividend Aristocats. This list limits the results to S&P 500 companies that have increased their dividends for 25 consecutive years or more. Having these filters set, I ran the screen and got 6 hits: I arranged the stocks in order from highest to lowest analyst ratings and selected the top three. However, Barchart Trend Seeker ® works in conjunction with Barchart Opinion to generate a complete analysis of stocks, and a buy signal from Trend Seeker ® may not necessarily mean a buy signal from Barchart Opinion or overall. For that reason, I'll remove XOM, CVX, and ALB from the list, as their opinion ratings are 'sell' - at least at the time I wrote this. With that out of the way, let's discuss the only three top Dividend Aristocrats on the on the list, starting with number one: Abbott Laboratories (ABT) Abbott is one of the most diversified healthcare companies in the world - and a frequent name featured in my top dividend stock lists. The company develops and markets medical devices, diagnostics, nutritional products, and branded generic medicines, and it is so well-known that there's a good chance that you or close family members are using its products. Abbott pays an annual $2.36 dividend, which translates to a yield of around 1.73% based on its current trading price. Trend Seeker ® Data ABT stock has a 100% overall buy rating based on Barchart Opinion and Trend Seeker, which, unsurprisingly, is based on a 100% buy rating across short, medium, and long-term indicators. It has maintained that rating from last month. However, its short-term averages are weakening as it approaches its first resistance point at $137.07, so it might be prudent to wait and see if it crosses above that or drops to its nearest support level before deciding on the stock. Caterpillar Inc (CAT) When you see heavy equipment on construction sites, you know there's going to be a Caterpillar product or machine right there. The company is a global manufacturer of construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and locomotives. It operates across many industries, including infrastructure, energy, and transportation. It also offers financing options under Cat Financial to help clients acquire their products more easily. The company pays a $5.64 annual dividend, which translates to around a 1.56% yield. Trend Seeker ® Data CAT has been leaning towards the sell side in recent times, although current price action - particularly when it broke through its short-term resistance-turned-support level at around $358.55 - has pushed its overall rating to a weak buy. Result? This can be a great buying opportunity for those who want to ride its growth up. International Business Machines (IBM) IBM was like Google or Microsoft back in the day, being one of the first companies to heavily and successfully focus on technology. Back then, offices were filled with the company's computers and devices. Although it lost a lot of traction in the 90s, the company is now making a grand comeback as a relevant player in the AI-heavy and quantum tech space. Dividend-wise, the company pays $6.72 annually, which translates to approximately a 2.39% yield — the highest on this list. Trend Seeker ® Data The company has had a strong run, with IBM stock up 27.84% year-to-date and 66.29% in the last twelve months, with the stock reaching a new all-time high of $283.06 on Thursday, June 12, 2025. It also maintains high current strength and direction scores. This tells me that IBM stock has the momentum to move higher, though a bit of profit-taking may be around the corner. I'd be cautious during the next few trading sessions, especially if the stock reaches around $285 and $290, as they're the closest psychological resistance levels for the stock. Final Thoughts These three Dividend Aristocrats are primed for a bullish trend, and they could be a great addition to your portfolio with the significant yield it can bring. If you are a long-term investor looking to maximize gains, these stocks are worth considering. However, these are based on current signals and analysis - which can change at the drop of a dime. That's why it's crucial to monitor the markets as and when you trade.
